These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11230872)

  • 1. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia.
    Volkow ND; Ding YS; Fowler JS; Gatley SJ
    Biol Psychiatry; 2001 Feb; 49(3):211-20. PubMed ID: 11230872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.
    Nordberg A
    Biol Psychiatry; 2001 Feb; 49(3):200-10. PubMed ID: 11230871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET studies and cholinergic therapy in Alzheimer's disease.
    Nordberg A
    Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
    Lemière J; Van Gool D; Dom R
    Acta Neurol Belg; 1999 Jun; 99(2):96-106. PubMed ID: 10427352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Sabri O; Meyer PM; Gräf S; Hesse S; Wilke S; Becker GA; Rullmann M; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Tiepolt S; Fischer S; Deuther-Conrad W; Hegerl U; Barthel H; Schönknecht P; Brust P
    Brain; 2018 Jun; 141(6):1840-1854. PubMed ID: 29672680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease.
    Kamkwalala AR; Newhouse PA
    Curr Alzheimer Res; 2017; 14(4):377-392. PubMed ID: 27697062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.
    Vesey R; Birrell JM; Bolton C; Chipperfield RS; Blackwell AD; Dening TR; Sahakian BJ
    CNS Drugs; 2002; 16(7):485-500. PubMed ID: 12056923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Richter N; Beckers N; Onur OA; Dietlein M; Tittgemeyer M; Kracht L; Neumaier B; Fink GR; Kukolja J
    Brain; 2018 Mar; 141(3):903-915. PubMed ID: 29309600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical studies in Alzheimer patients with positron emission tomography.
    Nordberg A
    Behav Brain Res; 1993 Nov; 57(2):215-24. PubMed ID: 7906947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A
    Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinic treatment of Alzheimer's disease.
    Newhouse PA; Potter A; Kelton M; Corwin J
    Biol Psychiatry; 2001 Feb; 49(3):268-78. PubMed ID: 11230878
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of positron emission tomography imaging in understanding Alzheimer's disease.
    Barthel H; Seibyl J; Sabri O
    Expert Rev Neurother; 2015 Apr; 15(4):395-406. PubMed ID: 25752209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based pharmacotherapy of Alzheimer's disease.
    Evans JG; Wilcock G; Birks J
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A; Albuquerque EX
    Eur J Pharmacol; 2000 Mar; 393(1-3):165-70. PubMed ID: 10771010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET.
    Nordberg A
    Acta Neurol Scand Suppl; 1993; 149():62-5. PubMed ID: 8128843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroimaging in Alzheimer's disease: relevance for treatment.
    van Dyck CH
    Curr Psychiatry Rep; 2001 Feb; 3(1):13-9. PubMed ID: 11177754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.
    Nordberg A; Lundqvist H; Hartvig P; Andersson J; Johansson M; Hellstrŏm-Lindahi E; Långström B
    Dement Geriatr Cogn Disord; 1997; 8(2):78-84. PubMed ID: 9065319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.